An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity

Simple item page
dc.contributor.authorZapata, Juan Carlosen
dc.contributor.authorPoonia, Bhawnaen
dc.contributor.authorBryant, Josephen
dc.contributor.authorDavis, Harryen
dc.contributor.authorAteh, Eugeneen
dc.contributor.authorGeorge, Laneaen
dc.contributor.authorCrasta, Oswald R.en
dc.contributor.authorZhang, Yanen
dc.contributor.authorSlezak, Tomen
dc.contributor.authorJaing, Crystalen
dc.contributor.authorPauza, C. D.en
dc.contributor.authorGoicochea, Marcoen
dc.contributor.authorMoshkoff, Dmitryen
dc.contributor.authorLukashevich, Igor S.en
dc.contributor.authorSalvato, Maria S.en
dc.date.accessioned2013-03-19T20:09:00Zen
dc.date.available2013-03-19T20:09:00Zen
dc.date.issued2013-02-12en
dc.date.updated2013-03-19T20:09:00Zen
dc.description.abstractBackground Lassa hemorrhagic fever (LHF) is a rodent-borne viral disease that can be fatal for human beings. In this study, an attenuated Lassa vaccine candidate, ML29, was tested in SIV-infected rhesus macaques for its ability to elicit immune responses without instigating signs pathognomonic for arenavirus disease. ML29 is a reassortant between Lassa and Mopeia viruses that causes a transient infection in non-human primates and confers sterilizing protection from lethal Lassa viral challenge. However, since the LHF endemic area of West Africa also has high HIV seroprevalence, it is important to determine whether vaccination could be safe in the context of HIV infection. Results SIV-infected and uninfected rhesus macaques were vaccinated with the ML29 virus and monitored for specific humoral and cellular immune responses, as well as for classical and non-classical signs of arenavirus disease. Classical disease signs included viremia, rash, respiratory distress, malaise, high liver enzyme levels, and virus invasion of the central nervous system. Non-classical signs, derived from profiling the blood transcriptome of virulent and non-virulent arenavirus infections, included increased expression of interferon-stimulated genes (ISG) and decreased expression of COX2, IL-1β, coagulation intermediates and nuclear receptors needed for stress signaling. All vaccinated monkeys showed ML29-specific antibody responses and ML29-specific cell-mediated immunity. Conclusion SIV-infected and uninfected rhesus macaques responded similarly to ML29 vaccination, and none developed chronic arenavirus infection. Importantly, none of the macaques developed signs, classical or non-classical, of arenavirus disease.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationVirology Journal. 2013 Feb 12;10(1):52en
dc.identifier.doihttps://doi.org/10.1186/1743-422X-10-52en
dc.identifier.urihttp://hdl.handle.net/10919/19291en
dc.language.isoenen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.holderJuan C Zapata et al.; licensee BioMed Central Ltd.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleAn attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunityen
dc.title.serialVirology Journalen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 2 of 2
Name:
1743-422X-10-52.xml
Size:
96.66 KB
Format:
Extensible Markup Language
Download
Thumbnail Image
Name:
1743-422X-10-52.pdf
Size:
1.12 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.5 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journal Articles, BioMed Central and SpringerOpen
Scholarly Works, Fralin Life Sciences Institute